Gujarat Themis Biosyn Limited (BOM: 506879)

India flag India · Delayed Price · Currency is INR
350.40
+9.30 (2.73%)
At close: Sep 10, 2024
226.05%
Market Cap 38.18B
Revenue (ttm) 1.59B
Net Income (ttm) 546.78M
Shares Out 108.97M
EPS (ttm) 5.01
PE Ratio 69.89
Forward PE n/a
Dividend 0.67 (0.19%)
Ex-Dividend Date Jul 15, 2024
Volume 144
Open 339.25
Previous Close 341.10
Day's Range 339.25 - 365.00
52-Week Range 102.75 - 389.90
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Nov 11, 2024

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis; Rifamycin-O; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India. [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 1981
Employees 159
Stock Exchange Bombay Stock Exchange
Ticker Symbol 506879
Full Company Profile

Financial Performance

In 2023, Gujarat Themis Biosyn's revenue was 1.70 billion, an increase of 14.45% compared to the previous year's 1.48 billion. Earnings were 591.63 million, an increase of 2.06%.

Financial Statements

News

There is no news available yet.